Former Chief Executive Officer · Alaunos Therapeutics, Inc. (TCRT)

Kevin Boyle

A named executive officer of Alaunos Therapeutics in every fiscal year CompBrief holds from FY2023 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$392,500

Salary $317,500Stock awards $0

FY2023: $1,986,946

2nd of 4 named executive officers at Alaunos Therapeutics by FY2024 total.

4 named officers on file for Alaunos Therapeutics, FY2024

Kevin Boyle’s pay file — $29

  • 2 fiscal years of pay, line by line
  • TCRT’s disclosed peer group of 1 company

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Alaunos Therapeutics’s whole pay program stands against its peers

  • Alaunos Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TCRT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 21, 2025 (DEF 14A).

Free

Get Kevin Boyle’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Kevin Boyle compensation by year

Alaunos Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Alaunos Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024
Salary$617,836$317,500
Bonus$270,000$0
Stock awards—$0
Option awards$689,580$0
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$409,529$75,000
Total$1,986,946$392,500

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Alaunos Therapeutics, Inc. DEF 14A filed May 21, 2025, accession 0001193125-25-123677, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Alaunos Therapeutics, Inc. filed document, accession 0001193125-25-123677. Every figure is read from that document and cited to the page and table it appears in. Filed May 21, 2025.

$2.0M
$393K
FY23
FY24
SalaryBonusOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU656,250$426,563—
Option1,804,688—$1.64
Option1,625,000—$0.66

Per the Outstanding Equity Awards at Fiscal Year-End table in Alaunos Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Alaunos Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Melinda LackeyLegal & Administration, Corporate Secretary$430,370
Kevin Boyle · this pageFormer Chief Executive Officer$392,500
Dale HogueInterim Chief Executive Officer$308,344
Ferdinand GroenewaldVice President, Finance$162,304

The full Alaunos Therapeutics compensation record

free company brief

This page is one person within Alaunos Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Alaunos Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Alaunos Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Kevin Boyle's compensation dossier · One-time report. No refunds.